IMGN

Latest articles

12d
Market Watch
Immunogen secondary offering priced below Friday's closing priceImmunogen Inc. IMGN, -2.56% priced its secondary offering below the price of th
Market Watch / Posted 12 days ago
Immunogen Inc. IMGN, -2.56% priced its secondary offering below the price of the close of shares on Friday, according to a filing with the Securities and Exchange Commission. The biotech company priced 14.5 million shares at $6.50 apiece, with an... Read more
13d
Business Wire
ImmunoGen Announces Pricing of Public Offering of Common StockWALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN) today announced
Business Wire / Posted 13 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN) today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price of $6.50 per share, before underwriting discounts. In addition,... Read more
14d
Market Watch
Immunogen shares fall after secondary share offering announcedImmunogen Inc. IMGN, +2.35% shares fell in the extended session Wednesday after
Market Watch / Posted 14 days ago
Immunogen Inc. IMGN, +2.35% shares fell in the extended session Wednesday after the biotech company announced a secondary offering of shares. Immunogen shares fell 10% to $7.05 after hours. The company said it plans to offer 13 million shares, and... Read more
18d
FOX Business
Exelixis, Inc. vs. Immunogen, Inc.thanks to continued momentum for its kidney cancer drug Cabometyx. But it's bee
FOX Business / Posted 18 days ago
thanks to continued momentum for its kidney cancer drug Cabometyx. But it's been a really great year for Immunogen(NASDAQ: IMGN): The stock has soared nearly 270%. The past is the past, though. Which of these cancer-focused biotech stocks is the... Read more
3 related articles
18d
FOX Business
Exelixis, Inc. vs. Immunogen, Inc.thanks to continued momentum for its kidney cancer drug Cabometyx. But it's bee
FOX Business / Posted 18 days ago
thanks to continued momentum for its kidney cancer drug Cabometyx. But it's been a really great year for Immunogen(NASDAQ: IMGN): The stock has soared nearly 270%. Continue Reading Below The past is the past, though. Which of these cancer-focused... Read more
3 related articles

In this news